Melanoma Matters
Melanoma Matters Pod
1 Listener
All episodes
Best episodes
Seasons
Top 10 Melanoma Matters Episodes
Goodpods has curated a list of the 10 best Melanoma Matters episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Melanoma Matters for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Melanoma Matters episode by adding your comments to the episode page.
Ep 01: CheckMate-067
Melanoma Matters
10/14/24 • 24 min
In this inaugural episode of Melanoma Matters, hear our what, why, and thank yous. Thank you (luv-u) to our producer big sister (general) Kippy, to David Gedge and The Wedding Present for use of their song "My Favourite Dress," and to the Uromigos duo of Tom & Brian for showing us what is possible.
In Episode 01, Sapna Patel and James Larkin discuss the CheckMate 067 study, a randomized phase three trial for frontline treatment of metastatic melanoma. They highlight the key findings, including improved progression-free survival, overall survival, and objective response rate with the combination of nivolumab and ipilimumab compared to monotherapy. They also discuss the importance of long-term follow-up and the management of toxicities associated with the combination therapy.
Keywords
melanoma, CheckMate 067, frontline treatment, metastatic melanoma, nivolumab, ipilimumab, combination therapy, monotherapy, progression-free survival, overall survival, objective response rate, toxicity
Takeaways
The combination of nivolumab and ipilimumab showed improved outcomes in progression-free survival, overall survival, and objective response rate compared to monotherapy in the CheckMate 067 study.
Long-term follow-up is important to assess the durability of treatment benefits and the development of long-term side effects.
Toxicities associated with combination therapy need to be managed, and treatment-free intervals can be considered without compromising long-term benefits.
Future trials should focus on capturing data on the development of CNS metastasis and melanoma-specific survival.
Viewer questions may be incorporated in future episodes to provide additional insights and engage the audience.
Sound Bites
"CheckMate 067: Frontline treatment of metastatic melanoma with nivolumab and ipilimumab"
"Treatment-free intervals after immune checkpoint inhibitor, particularly the combinations, does not necessarily compromise long-term benefit"
"Numerically, ipilimumab-nivolumab combination fared better in the development of brain metastases compared to anti-PD-1 monotherapy"
Chapters
00:00 Introduction and Background
05:30 CheckMate 067 Study: Improved Outcomes with Combination Therapy
13:01 Comparison with Pembrolizumab Monotherapy
1 Listener
Ep 49: Melanoma Patient Network Europe with Bettina Ryll
Melanoma Matters
10/14/24 • 39 min
Summary
In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel engage with Bettina Ryll, founder of the Melanoma Patient Network Europe (MPNE). Bettina shares her personal journey from being a physician to becoming a patient advocate after her husband's battle with metastatic melanoma. The conversation explores the evolution of patient support networks, the challenges faced in healthcare systems, and complex adaptive systems. Bettina emphasizes the need for systemic change to improve patient access to treatments and highlights the importance of understanding the interconnectedness of healthcare, economics, and patient outcomes.
Keywords
melanoma, patient advocacy, healthcare systems, immunotherapy, patient networks, Bettina Ryll, MPNE, clinical trials, healthcare access, systemic change
Takeaways
Bettina Ryll founded MPNE after her husband's battle with melanoma.
Patient networks are crucial for sharing knowledge and support.
Understanding the healthcare system is key to advocating for patients.
Immunotherapy presents complex challenges that need addressing.
Systemic change is necessary for improving patient access to treatments.
The pharmaceutical landscape is influenced by economic factors.
Patients should not be treated as victims of their circumstances.
Action is often more effective than extensive planning.
Collaboration and community (and ferocious energy) are essential for driving change.
Sound Bites
"I just started explaining science."
"We are sentinels for issues."
"We must be standing for something."
Chapters
00:00 Introduction to Bettina Ryll
06:19 The Formation of Melanoma Patient Network Europe
11:51 Understanding Patient Needs and Systemic Issues
17:54 Challenges in Immunotherapy and Clinical Trials
23:47 Healthcare and Patient Access as Complex Adaptive Systems
29:25 The Role of Community and Collaboration in Change
1 Listener
Ep 03: CheckMate-204
Melanoma Matters
10/14/24 • 27 min
Summary
In this conversation, James Larkin and Sapna Patel discuss the findings of the Checkmate 204 study, which looked at the treatment of brain metastases from melanoma using nivolumab and ipilimumab. They highlight that the combination therapy showed efficacy in asymptomatic patients with brain metastases, with a 55% intracranial clinical benefit rate. They also discuss the importance of early detection and treatment of brain metastases, as well as the role of local therapies such as surgery and stereotactic radiotherapy. The conversation emphasizes the need to minimize the use of steroids and start systemic treatment as soon as possible.
Keywords
Checkmate 204, brain metastases, melanoma, nivolumab, ipilimumab, intracranial clinical benefit, asymptomatic, local therapy, surgery, stereotactic radiotherapy, steroids, systemic treatment
Takeaways
- The combination therapy of nivolumab and ipilimumab showed efficacy in asymptomatic patients with brain metastases from melanoma.
- Early detection and treatment of brain metastases is crucial for improving outcomes.
- Local therapies such as surgery and stereotactic radiotherapy can be used for symptomatic brain metastases.
- Minimizing the use of steroids and starting systemic treatment as soon as possible is important.
- The systemic standard of care for brain metastases from melanoma is ipinivo.
Sound Bites
"NIVO-IPI is active in the brain for asymptomatic patients."
"If you have an asymptomatic untreated brain met measuring at least 0.5 centimeters, there's activity with this combination."
"When I was learning how to treat this disease 20 years ago, having brain metastasis was basically a death sentence. Now we're talking about three-year data and it looks like the possibility of cure in some of these patients."
Chapters
00:00 Introduction and Overview of Checkmate 204
06:33 Improvement in Outcomes for Brain Metastases
11:47 Importance of Early Detection and Treatment
23:16 Practical Considerations and Conclusion
25:38 Fact Check
1 Listener
Ep 02: RELATIVITY-047
Melanoma Matters
10/14/24 • 26 min
Summary
In this episode of Melanoma Matters, James Larkin and Sapna Patel discuss the RELATIVITY 047 trial, which evaluated the combination of nivolumab and relatlimab in frontline metastatic melanoma. They cover the trial design, response rates, overall survival, toxicity, and the role of PD-L1 expression in treatment decisions. They also explore the potential use of nivolumab and relatlimab in patients with brain metastases. While the combination showed a superior progression-free survival compared to nivolumab monotherapy, it did not demonstrate a significant overall survival benefit. The tolerability profile was better than ipilimumab and nivolumab combination therapy but had more side effects than anti-PD-1 monotherapy.
Keywords
RELATIVITY 047, nivolumab, relatlimab, metastatic melanoma, checkpoint inhibitors, PD-L1 expression, response rates, overall survival, toxicity, brain metastases
Takeaways
The RELATIVITY 047 trial evaluated the combination of nivolumab and relatlimab in frontline metastatic melanoma.
The combination showed a superior progression-free survival compared to nivolumab monotherapy.
There was no significant overall survival benefit observed in the trial.
The tolerability profile of nivolumab and relatlimab was better than ipilimumab and nivolumab combination therapy but had more side effects than anti-PD-1 monotherapy.
PD-L1 expression may play a role in treatment decisions, but its use as a biomarker is still debated.
The efficacy of nivolumab and relatlimab in patients with brain metastases is an area of interest.
Further follow-up and data analysis are needed to fully understand the long-term outcomes of the combination therapy.
Sound Bites
"Relativity 047 was a randomized phase three study for frontline metastatic melanoma using dual checkpoint inhibition."
"Relativity 047 is hitting some marks, but it's missing others. It has a PFS benefit but no OS benefit."
"The CheckMate 067 trial had a sicker population with higher LDH and declining performance status compared to RELA 047."
Chapters
00:00 Introduction and Trial Background
04:47 Comparison with CheckMate 067 and Study Population Differences
09:48 Challenges of Using PD-L1 Expression as a Biomarker
24:19 Fact Check: Citations and Clarifications
1 Listener
Ep 42: RELATIVITY 020
Melanoma Matters
10/14/24 • 31 min
Summary
James' favorite moments from #ESMO24 include footie and a not-so-chance encounter with NEJM Editor-in-Chief, Eric Rubin.
In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Relativity 020 study, which focuses on Nivo Rela after PD-1 exposure in melanoma patients. They reflect on their experiences at ESMO, including networking and memorable moments, before diving into the details of the study, including patient cohorts, treatment efficacy, and the challenges faced in clinical trials. The conversation also touches on the role of CTLA-4 therapies and the complexities of treatment sequencing in melanoma care.
Keywords
melanoma, ESMO, Relativity 020, Nivo Rela, PD-1, CTLA-4, clinical trials, patient access, immunotherapy, oncology
Takeaways
The Relativity 020 study explores Nivo Rela after PD-1 exposure in melanoma.
Networking at ESMO is crucial for sharing insights and experiences.
Patient access to treatments is a significant challenge in clinical trials.
The efficacy of Nivo Rela in heavily pretreated patients is limited.
CTLA-4 therapies show low response rates in PD-1 refractory patients.
Understanding treatment sequences is essential for optimizing patient outcomes.
The importance of academic trials in addressing knowledge gaps in melanoma treatment.
Elevated LDH levels are a concerning biomarker in treatment response.
Collaboration among investigators is vital for advancing melanoma research.
The conversation highlights the need for ongoing research and trials in melanoma.
Chapters
00:00 Introduction and ESMO Highlights
03:30 Reflections on ESMO 2024
06:21 The Relativity 020 Study Overview
09:17 Patient Perspectives and Clinical Trials
12:20 Challenges in European Clinical Trials
15:36 Efficacy of NIVO-RELA in Refractory Melanoma
18:40 Discussion on CTLA-4 Therapies
21:21 Future Directions in Melanoma Treatment
1 Listener
Ep 37: CheckMate 511
Melanoma Matters
10/14/24 • 31 min
Summary
In this episode of Melanoma Matters, host James Larkin uses his 1-800-Operator voice until co-host Sapna Patel reminds him to use his podium voice. There is a noisy wardrobe choice (SP) and a fact check of a fact check (JL).
Sapna and James have an in-depth conversation of the Checkmate 511 study, discussing its implications for treatment regimens in melanoma. They delve into the nuances of type 1 and type 2 errors, analyze the results of the study, and consider the long-term follow-up data. The conversation also explores global perspectives on treatment practices and the importance of understanding toxicity and efficacy in clinical settings.
Keywords
Checkmate 511, melanoma, type 1 error, type 2 error, treatment regimens, efficacy, toxicity, global perspectives, long-term follow-up, clinical practice
Takeaways
Checkmate 511 is a widely cited study in melanoma treatment.
Type one error relates to the alpha of the study, while type two error is related to sample size.
The study showed a lower incidence of grade 3 to 5 AEs with Nivo 3 - Ipi 1 compared to Nivo 1 -Ipi 3.
Long-term follow-up is crucial for understanding the efficacy of treatment regimens.
Global perspectives on treatment regimens vary, especially regarding reimbursement and labeling.
The study's findings have influenced practice in the U.S., despite a lack of formal publication.
Concerns remain about the efficacy of lower doses in specific patient populations, such as those with brain metastases.
The conversation highlights the importance of ongoing research and follow-up studies in melanoma treatment.
Understanding statistical errors is essential for interpreting clinical trial results.
The hosts express a desire for more comprehensive data and follow-up on the Checkmate 511 study.
Sound Bites
"This is a fact check of a fact check."
"Type one error is related to the alpha of a study."
"The incidence of grade 3 to 5 AEs was 34% with Nivo 3 -Ipi 1."
Chapters
00:00 Introduction and Volume Issues
04:50 Overview of Checkmate 511 Study
09:59 Concerns about Lack of Published Follow-Up Data
16:00 Demographics and Subgroups in Checkmate 511 Study
16:44 Implementation of Inverted Dosing Regimen Globally
19:01 Caution and Considerations with Inverted Dosing Regimen
23:45 Fact Check
25:08 Comparing Regimens in the BRAF Mutant Population
29:16 Fact-Checking 'Up in the Air'
29:50 Fact Check of a Fact Check (BRAF)
Ep 35 TRAILER: End of Life care
Melanoma Matters
10/14/24 • 1 min
A trailer on our conversation about end of life care in melanoma
Ep 47: TRICOTEL with Andreas Schmitt
Melanoma Matters
10/14/24 • 40 min
Summary
In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel welcome Dr. Andreas Schmitt to discuss various aspects of melanoma treatment, including the importance of supplementary data in clinical trial reports, the implications of the TRICOTEL study, and the role of PD-L1 as a biomarker. The conversation highlights the significance of peer review and academic collaboration in oncology, as well as the impact of regulatory decisions on patient treatment options. The episode concludes with a discussion on the findings of the republished TRICOTEL study and the importance of inquiry in medical practice.
Keywords
melanoma, oncology, clinical trials, PD-L1, TRICOTEL study, symptomatic brain metastasis, supplementary data, peer review, academic collaboration, cancer treatment, biomarkers
Takeaways
The importance of looking at supplementary data in clinical trials is a recurring theme in this podcast.
The TRICOTEL study revealed significant findings regarding treatment for symptomatic brain metastasis, but there was controversy over the coding of these patients as symptomatic.
Peer review and academic collaboration are crucial in addressing discrepancies in clinical data.
PD-L1 expression may not be a reliable biomarker for treatment decisions in melanoma.
Regulatory decisions can impact patient access to effective treatments.
The objective response rate in the TRICOTEL republication was lower than in the initial (retracted) report.
Inquiring and questioning data is an essential feature of an intrepid (F)ellow.
Continuous reading and inquiry are vital for oncologists to stay informed.
Sound Bites
"Why I'm an oncologist?"
"Look at the supplementaries!"
"We redesigned the SWOG S2000 study after the TRICOTEL presentation to drop the asymptomatic cohort."
Chapters
00:00 Introduction and Lighthearted Banter
00:30 Meet the Guests: Andreas Schmitt
01:34 Always read the Supplemental Appendix!
06:31 The TRICOTEL Controversy Unveiled
10:43 Symptomatic Cohort in TRICOTEL
18:35 Peer Review in Publications
20:20 Republication of the TRICOTEL data
22:08 Editorial(s) on PD-L1 as a Biomarker
32:38 Concluding Thoughts on PD-L1
10/14/24 • 28 min
Teaser: Find out Allison's favorite body part, had she been an orthopedic surgeon (and James' 2nd favorite.. from the movie Sleeper)
Summary
In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Dr. Allison Betof-Warner, Director of the Advanced Melanoma Program at Stanford University. The conversation explores Dr. Betof-Warner's journey into oncology, her passion for CrossFit, and the significant role of exercise in cancer prevention and treatment. They discuss the emerging field of exercise oncology, the importance of strength training for cancer patients, and the latest advancements in cellular therapy for melanoma, particularly in patients with brain metastases. Hot take: physical activity is a vital component of cancer treatment.
Keywords
melanoma, oncology, exercise oncology, cancer prevention, cellular therapy, CrossFit, strength training, TIL therapy, patient care, health and wellness
Takeaways
Exercise is crucial throughout the cancer journey, from prevention to treatment.
The field of exercise oncology is growing, focusing on the benefits of physical activity for cancer patients.
Strength training is now recommended for cancer patients to maintain function and prevent cachexia.
Patients should be encouraged to engage in regular physical activity, even during treatment.
Research shows that exercise can improve tumor vascular structure and enhance chemotherapy delivery.
The safety of exercise during cancer treatment has been increasingly supported by research.
Cellular therapy is a promising area of research for melanoma, especially in patients with brain metastases.
Patient education regarding exercise during treatment is important.
A multidisciplinary approach to cancer care, including physical therapy, is essential for optimizing patient outcomes.
Titles
The Role of Exercise in Cancer Treatment
Cellular Therapy in Melanoma with Brain Metastasis
Sound Bites
"I shifted the direction of my research, did my PhD in cancer research."
"Exercise spans the cancer journey."
"Exercise helps prevent cancer cachexia."
Chapters
00:00 Introduction
03:24 Allison's Journey to Oncology and CrossFit
06:32 The Intersection of Exercise and Cancer
09:33 Exercise Oncology: Benefits and Guidelines
19:22 Safety and Efficacy of TIL Therapy for CNS disease
25:22 Patient Exercise During Cell Therapy
Ep 36: Indirect comparison CM 067 v RELA 047
Melanoma Matters
10/14/24 • 24 min
Summary
James is back from holiday and tells us the peak, pit, and bud of his time away. (Spoiler: the pit was NOT a broken tooth!) He also shares a tip for time management and email hygiene on holiday. Sapna makes an unfortunate wardrobe choice (noisy, not visual).
In this episode of Melanoma Matters, hosts Sapna and James delve into the complexities of indirect treatment comparisons in melanoma therapy. They discuss a recently published paper comparing nivolumab plus relatlimab versus nivolumab plus ipilimumab, exploring the statistical methodologies, clinical implications, and biological plausibility of the findings. The conversation highlights the importance of understanding treatment options, patient selection, and future directions in melanoma treatment strategies.
Keywords
melanoma, indirect treatment comparison, nivolumab, relatlimab, ipilimumab, clinical trials, biomarkers, treatment strategies, patient care, oncology
Takeaways
Indirect treatment comparisons are a valid methodology.
Statistical methodologies can be complex but are essential for comparisons.
The efficacy of treatments can vary based on patient characteristics.
Biological plausibility is crucial in interpreting treatment outcomes.
LDH levels can be significant biomarkers in treatment decisions.
Ipilimumab plus nivolumab is considered a potent treatment regimen.
Patient experience and clinical data inform treatment choices.
Future strategies may involve combining therapies for better outcomes.
Understanding the nuances of clinical trials is vital for practitioners.
Reimbursement discussions may hinge on the findings of such studies.
Sound Bites
"I don't understand the statistics and the principles behind it."
"It's an accepted methodology, I think is the first thing to say."
"It's a reasonable exercise."
Chapters
00:00 Introduction and Rapid Fire Questions
06:49 Understanding Indirect Treatment Comparison
11:55 Comparison of Nevolumab Plus Relatlimab vs. Nevolumab Plus Ipilimumab
14:40 LDH as a Biomarker in Melanoma
20:28 Benefit of Ipnevo for BRAF Mutated Patients
23:17 Considerations for Targeted Therapy Before Immunotherapy
Show more best episodes
Show more best episodes
FAQ
How many episodes does Melanoma Matters have?
Melanoma Matters currently has 61 episodes available.
What topics does Melanoma Matters cover?
The podcast is about Health & Fitness, Medicine and Podcasts.
What is the most popular episode on Melanoma Matters?
The episode title 'Ep 49: Melanoma Patient Network Europe with Bettina Ryll' is the most popular.
What is the average episode length on Melanoma Matters?
The average episode length on Melanoma Matters is 27 minutes.
When was the first episode of Melanoma Matters?
The first episode of Melanoma Matters was released on Oct 14, 2024.
Show more FAQ
Show more FAQ